Concepedia
Statistics
Publications
13
Citations
2.3K
H-Index
12
Active since
2002
Affiliations
Seagen (United States)(Current)
Amgen (United States)
Zymeworks (Canada)
University of Washington
Fred Hutch Cancer Center
Kevin J. Hamblett is an author at Seagen (United States) specializing in oncology, antibody-drug conjugates, and pharmacology.
Publications per year
2002–2023
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations
Pharmacy, Oncology, Pharmacology +17
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Michael Sun, Kevin S. Beam, Charles G. Cerveny et al. · Bioconjugate Chemistry · 2005 · 365 citations · Full text
Pharmacy, Biochemistry, Pharmacology +17
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F. McDonagh, Eileen Turcott, Lori Westendorf et al. · Protein Engineering Design and Selection · 2006 · 237 citations · Full text
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
Kevin J. Hamblett, Allison P. Jacob, Jesse L. Gurgel et al. · Cancer Research · 2015 · 135 citations
Life Sciences, Molecular Biology, Oncology +17
AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu et al. · Molecular Cancer Therapeutics · 2015 · 100 citations
Medicine, Oncology, Pharmacology +17
1–5 of 13